Table 3.
Summary of gene mutations in colorectal cancer patients
Gene |
Tumor tissue
|
Preoperative feces
|
Postoperative stools
|
|||
Total number of mutations
|
Mutation frequency
|
Total number of mutations
|
Mutation frequency
|
Total number of mutations
|
Mutation frequency
|
|
TP53 | 40 | 62.00% (31/50) | 27 | 59.26% (16/27) | 7 | 31.58% (6/19) |
APC | 15 | 24.00% (12/50) | 3 | 11.11% (3/27) | 0 | 0 |
KRAS | 30 | 58.00% (29/50) | 11 | 37.04% (10/27) | 0 | 0 |
PIK3CA | 13 | 22.00% (11/50) | 1 | 3.70% (1/27) | 2 | 10.53% (2/19) |
FBXW7 | 5 | 10.00% (5/50) | 1 | 3.70% (1/27) | 0 | 0 |
GNAS | 2 | 4.00% (2/50) | 1 | 3.70% (1/27) | 0 | 0 |
PTEN | 11 | 22.00% (11/50) | 1 | 3.70% (1/27) | 0 | 0 |
ABL1 | 0 | 0 | 1 | 3.70% (1/27) | 0 | 0 |
PDGFRA | 12 | 24.00% (12/50) | 8 | 29.63% (8/27) | 6 | 31.58% (6/19) |
ATM | 1 | 2.00% (1/50) | 0 | 0 | 0 | 0 |
SMAD4 | 1 | 2.00% (1/50) | 0 | 0 | 0 | 0 |
BRAF | 2 | 4.00% (2/50) | 0 | 0 | 2 | 10.53% (2/19) |
PTPN11 | 1 | 2.00% (1/50) | 0 | 0 | 0 | 0 |
NRAS | 1 | 2.00% (1/50) | 0 | 0 | 0 | 0 |
CTNNB1 | 3 | 6.00% (3/50) | 1 | 3.70% (1/27) | 0 | 0 |
STK11 | 2 | 4.00% (2/50) | 1 | 3.70% (1/27) | 0 | 0 |
AKT1 | 1 | 2.00% (1/50) | 1 | 3.70% (1/27) | 0 | 0 |
CDKN2A | 3 | 6.00% (3/50) | 4 | 7.41% (2/27) | 3 | 5.26% (1/19) |
HRAS | 21 | 42.00% (21/50) | 12 | 40.74% (11/27) | 8 | 42.11% (8/19) |
EGFR | 2 | 4.00% (2/50) | 2 | 7.41% (2/27) | 1 | 5.26% (1/19) |
IDH1 | 2 | 4.00% (2/50) | 2 | 7.41% (2/27) | 1 | 5.26% (1/19) |
NOTCH1 | 2 | 4.00% (2/50) | 0 | 0 | 2 | 5.26% (1/19) |
VHL | 0 | 0 | 1 | 3.70% (1/27) | 0 | 0 |
KIT | 7 | 14.00% (7/50) | 2 | 7.41% (2/27) | 4 | 21.05% (4/19) |
MET | 9 | 18.00% (9/50) | 5 | 18.52% (5/27) | 4 | 21.05% (4/19) |
MLH1 | 3 | 6.00% (3/50) | 2 | 7.41% (2/27) | 2 | 10.53% (2/19) |
MPL | 0 | 0 | 0 | 0 | 1 | 5.26% (1/19) |
Total number of mutations: The overall number of mutations of any gene in various samples. Mutation frequency: The number of people with mutations in various samples/total number of people.